Vaccitech PLC - ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VACC Nasdaq 8731 https://www.vaccitech.co.uk/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vaccitech PLC - ADR

Newsflash: Vaccitech plc (NASDAQ:VACC) Analysts Have Been Trimming Their Revenue Forecasts - May 19th, 2023 10:04 am
Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments - May 12th, 2023 12:00 pm
Revenues Working Against Vaccitech plc's (NASDAQ:VACC) Share Price - May 5th, 2023 11:33 am
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile - Apr 17th, 2023 1:00 pm
7 Thrilling Biotech Stocks for Aggressive Investors to Buy - Apr 5th, 2023 5:40 pm
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B - Mar 28th, 2023 12:00 pm
Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments - Mar 24th, 2023 12:06 pm
Vaccitech Says Prime-boost Vaccine Study Data In Women With Low-grade HPV Lesions Is 'Promising Step In Right Direction' - Mar 20th, 2023 4:44 pm
Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions - Mar 20th, 2023 12:00 pm
Owning 39% shares,institutional owners seem interested in Vaccitech plc (NASDAQ:VACC), - Mar 16th, 2023 10:47 am
11 High Growth UK Stocks to Buy - Mar 1st, 2023 11:01 am
Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer - Jan 30th, 2023 1:00 pm
Vaccitech (NASDAQ:VACC) adds US$10m to market cap in the past 7 days, though investors from a year ago are still down 73% - Jan 13th, 2023 10:24 am
Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases - Nov 21st, 2022 3:31 pm
Vaccitech Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag - Nov 13th, 2022 12:29 pm
Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments - Nov 10th, 2022 9:30 pm
Vaccitech to Present at Upcoming November Investors Conferences - Nov 9th, 2022 1:00 pm
Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B - Nov 7th, 2022 1:00 pm
Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300 - Nov 2nd, 2022 12:00 pm
Vaccitech Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 immunotherapeutic candidate for Chronic HBV Patients - Oct 31st, 2022 12:00 pm